中文 | English
 
毛斐




毛斐  博士  副教授


联系方式:

通讯地址:华东理工大学实验十八楼431室,邮编200237

邮箱:maofei@ecust.edu.cn


个人简介

20146月毕业于中山大学药学院药物化学专业,获博士学位,后进入华东理工大学药学院从事博士后研究,合作导师为李剑教授。201610月出站后留校工作,从事药物化学教学和科研工作,20189月晋升副教授。

作为项目负责人,先后主持国家自然科学基金青年基金1项、博士后科学基金(面上一等资助)1项、教育部高校基本科研业务费12017年入选上海市青年科技英才扬帆计划2018年入选华东理工大学青年英才培育计划”A类。

迄今已在国内外重要刊物如J. Med. Chem.; Eur. J. Med. Chem.; ACS Chem. Neurosci.等上发表SCI论文40余篇;申请发明专利14项(授权2项);参编论著1部(药物结构优化——设计策略和经验规则)。

  

主要研究方向

  1. 多靶点抗AD创新药物发现研究

  2. 抗耐药菌创新药物开发研究

  3. 抗肿瘤创新药物开发研究

  4. 老药二次开发研究

      

  

代表性论文 (#共同第一作者,*为通讯作者)

  1. Wenwen Liu#, Huan Wang#, Xiaokang Li#, Yixiang Xu, Jian Zhang, Wei Wang, Qi Gong, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. Bioorg. Med. Chem. 2018, 26, 3117–3125.

  2. Wei Ni#, Huan Wang#, Xiaokang Li#, Xinyu Zheng#, Manjiong Wang, Jian Zhang, Qi Gong, Dazheng Ling, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5). ACS Chem. Neurosci. 2018, 9, 1625–1636.

  3. Baoli Li#, Shuaishuai Ni#, Fei Mao#, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*. Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity. J. Med. Chem. 2018, 61, 224–250.

  4. Fei Mao#, Huan Wang#, Wei Ni#, Xinyu Zheng, Manjiong Wang, Keting Bao, Dazheng Ling, Xiaokang Li, Yixiang Xu, Haiyan Zhang*, Jian Li*. Design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (AChE) and phosphodiesterase 5 (PDE5) for the treatment of Alzheimer’s disease. ACS Chem. Neurosci. 2018, 9, 328–345.

  5. Hanwen Wei#, Fei Mao#, Shuaishuai Ni#, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections. Eur. J. Med. Chem. 2018, 145, 235–251.

  6. Yi-xiang Xu#, Huan Wang#, Xiao-kang Li, Sheng-nan Dong, Wen-wen Liu, Qi Gong, Tian-duan-yi Wang, Yun Tang, Jin Zhu, Jian Li*, Hai-yan Zhang*, Fei Mao*. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 2018, 143, 33–47.

  7. Xiaokang Li#, Huan Wang#, Yixiang Xu, Wenwen Liu, Xiaoxia Qiu, Jin Zhu, Fei Mao*, Haiyan Zhang*, Jian Li*. Novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of Alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. ACS Chem. Neurosci. 2017, 8, 2708–2721.

  8. Yanli Lu#, Fei Mao#, Xiaokang Li, Xinyu Zheng, Manjiong Wang, Qing Xu, Jin Zhu, and Jian Li*. Discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-KIT/PDGFRα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (GISTs). J. Med. Chem. 2017, 60, 5099–5119.

  9. Xiaokang Li#, Huan Wang#, Zhengyu Lu, Xinyu Zheng, Wei Ni, Jin Zhu, Yan Fu, Fulin Lian, Naixia Zhang, Jian Li*, Haiyan Zhang*, and Fei Mao*. Development of multifunctional pyrimidinylthiourea derivatives as potential anti-Alzheimer agents. J. Med. Chem. 2016, 59, 83268344.

  10. Fei Mao#, Qingya Kong#, Wei Ni, Xiang Xu, Dazheng Ling, Zhengyu Lu, Jian Li*. Melting point distribution analysis of the global approved and discontinued drugs: a Research for improving the success chance of drug design and discovery. ChemistryOpen, 2016, 5, 357–368.

  11. Fei Mao, Wei Ni, Xiang Xu, Hui Wang, Jing Wang, Min Ji, Jian Li*. Chemical structure-related drug-like criteria of global approved drugs. Molecules 2016, 21, 75; doi:10.3390/molecules21010075.

  12. Dengwei Wu#, Fei Mao#, Yan Ye, Jian Li, Chuanlian Xu*, Xiaomin Luo, Jing Chen*, Xu Shen. Policresulen as a novel inhibitor of NS2B/NS3 protease efficiently suppressed the replication of DENV2 virus. Acta Pharmacol. Sin. 2015, 36, 1126-1136.

  13. Fei Mao, Jianheng Li, Hui Wei, Ling Huang*, Xingshu Li*. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease.J. Enzym. Inhib. Med. Chem.2015,30, 995-1001.

  14. Fei Mao, Jun Yan, Jian-heng Li, Yang sun, Xian Jia, Ling Huang*, Xing-shu Li*. New Multi-Target-Directed Small Molecules Against Alzheimer's Disease: a Combination of Resveratrol and Clioquinol. Org. Biomol. Chem. 2014, 12, 5936-5944.

  15. Fei Mao, Jian-wen Chen*, Qi Zhou, Zong-hua Luo, Li Huang, Xing-shu Li*. Novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. Bioorg. Med. Chem. Lett.2013, 23, 6737-6742.

  16. Fei Mao, Ling Huang, Zong-hua Luo, Anqiu Liu, Chuan-jun Lu, Zhi-yong Xie*, Xingshu Li*. O-Hydroxyl or o-amino benzylamine-tacrine hybrids: Multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation. Bioorgan. Med. Chem.2012, 20, 5884-5892.



网页发布时间: 2018-10-22